BBIO vs NCLH · rev $438.2M vs P/E 16, rev $4.97B
BridgeBio Pharma Inc (BBIO) versus Norwegian Cruise Line Holdings Ltd (NCLH) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
Latest reported BBIO revenue for 2026-06-30 was $438.2M. Net income was -$322.4M. BBIO currently screens at market cap $13.24B.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
BBIO currently screens at market cap $13.24B. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
Not investment advice. Open the BBIO and NCLH stock pages for the full models.
Not investment advice.